OLIPHARM: sector benchmark
Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.
OLIPHARM
Summary
OLIPHARM does better than half of its sector on 2 of the 7 ratios compared.
- Current ratiobetter than 95%
- Working-capital ratiobetter than 54%
- Long-term debt ratiobetter than 10%
- Debt to equitybetter than 12%
- Solvencybetter than 30%
Solvency and debt
Solvency is below 70% of 27,710 sector peers: less favourable than the median.
Position against the sector stable since 2022.
Debt to equity is above 88% of 26,982 sector peers: in the least favourable quarter.
Position against the sector stable since 2022.
The long-term debt ratio is above 90% of 17,087 sector peers: in the least favourable quarter.
Position against the sector stable since 2022.
Liquidity
The current ratio is above 95% of 26,960 sector peers: in the most favourable quarter.
Position against the sector stable since 2022.
The working-capital ratio is above 54% of 27,590 sector peers: more favourable than the median.
Position against the sector stable since 2022.
Profitability
Return on equity is below 58% of 22,808 sector peers: less favourable than the median.
Position against the sector weakening since 2022.
Return on assets is below 58% of 27,770 sector peers: less favourable than the median.
Position against the sector stable since 2022.
Not computable
Interest coverage, Net margin, EBITDA margin, Gross margin, Days sales outstanding, Days payable outstanding, Days inventory. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.
Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 28 September 2026 via checked.be.